1.   Ligand is seeking another collaboration to develop diabetes drugs.

2.   Although the past decade has delivered a plethora of new diabetes drugs, not all have turned out to be as beneficial as first hailed.

3.   A few years ago a diabetes drug called Glucophage came on the market.

4.   Considered an industry laggard until last year, the introduction of its cholesterol-lowering drug Lipitor and diabetes drug Rezulin have pumped up heretofore lackluster earnings.

5.   Earlier this week, Glaxo said it had halted British sales of its new diabetes drug Romozin after six patients died in the U.S. and Japan from liver toxicity.

6.   Earlier this month, Warner-Lambert said it would put additional warnings on the label for the diabetes drug Rezulin, its second-best seller after Lipitor.

7.   Glaxo Wellcome Plc said it halted British sales of its new diabetes drug Romozin after six patients died in the U.S. and Japan from liver toxicity.

8.   If approved, Ergoset will compete against several other Type II diabetes drugs, including Metformin from Bristol-Myers Squibb Co.

9.   Its diabetes drug, Glucophage, and an anti-anxiety drug, BuSpar, could soon face competition.

10.   Japanese drugmaker Sankyo Co. plans to sell its new diabetes drug, Noscal, soon in the U.S., the company said.